Six departments to rectify drug safety and crack down on fake sales and sales
ZHONGSHAN G.H.L. TRADING CO., LTD. , https://www.ghltrade.com
A few days ago, the State Food and Drug Administration, in collaboration with the Ministry of Health, the Ministry of Industry and Information Technology, the State Administration for Industry and Commerce, and the Chinese Medicine Bureau, released the "Special Work Plan for Drug Safety Remediation." This initiative aims to address a range of critical issues, including the illegal promotion of false advertisements through online platforms and other media, the sale of counterfeit medicines via delivery services, and the misuse of non-pharmaceutical products like food, disinfectants, health supplements, and cosmetics as substitutes for real drugs.
The plan also emphasizes cracking down on the production and distribution of fake medicines, while focusing on strengthening oversight of pharmaceutical manufacturing, sourcing, and quality control. It calls for raising the standards for drug and medical device approvals, increasing on-site inspections, and accelerating the revision of regulatory guidelines. Additionally, the initiative targets violations such as "joint operations" and "ticket selling" in the pharmaceutical supply chain—practices that undermine the integrity of the market.
As part of the broader effort, the government is working to establish comprehensive systems for drug safety. This includes improving pharmaceutical quality management regulations, enhancing the monitoring and evaluation of adverse drug reactions, refining the drug approval process, and building a more robust electronic drug regulatory system. Over the next three years, the goal is to achieve full-process, real-time monitoring of drug production, distribution, transportation, storage, and delivery to healthcare institutions, significantly improving the overall regulatory capacity and effectiveness.
In addition to these measures, the plan includes public awareness campaigns on safe drug use, the development of a clear drug safety responsibility system, and the implementation of targeted inspections and supervision efforts. These steps are designed to ensure long-term stability and trust in the pharmaceutical sector, protecting both consumers and the integrity of the healthcare system.